Investigators assessed factors associated with 90- and 365-day mortality among veterans infected carbapenem-resistant Acinetobacter baumanii and carbapenem-resistant Pseudonomas aeruginosa.
Researchers compared clinical characteristics and outcomes among patients hospitalized with sepsis who were positive vs negative for COVID-19 infection.
Researchers assessed independent predictors of all-cause mortality within a 2-year period among adult patients admitted to an emergency department with suspected bacterial infections.
Researchers assessed whether the increased risk for dementia observed among older adults diagnosed with bacterial pneumonia differs by causative pathogen.
Researchers conducted a study that assessed antimicrobial resistance associated with specific Escherichia coli isolates in patients infected with E coli bacteremia.
Researchers conducted a study that assessed the rate of 90-day all-cause crude mortality vs attributable mortality among patients with candida bloodstream infections.
Investigators conducted a study to determine whether early antibiotic administration decreases the risk for progression to septic shock among patients with suspected sepsis.
Researchers conducted a meta-analysis to determine whether chlorhexidine cleansing effectively decreases the risk for healthcare-associated infections in neonates.
Infants born at all gestational ages with low-risk delivery characteristics have a low risk for EOS and may not require initiation of empiric antibiotic therapy.
Researchers conducted a study to determine whether the lactate dehydrogenase to albumin ratio is an independent prognostic factor predictive of in-hospital mortality in patients with lower respiratory tract infection.
Researchers conducted a study to compare outcomes among patients who underwent placement of either a midline or peripherally inserted central catheter due to either difficult vascular access or to receive antibiotic therapy.
Researchers conducted a study to assess the safety and efficacy of aminoglycosides or polymyxin monotherapy for the treatment of adults with complicated urinary tract infections caused by extensively drug-resistant Pseudomonas aeruginosa.